By Peter Loftus
The Wall Street Journal
Originally published September 10, 2012
Johnson and Johnson agreed to a last-minute settlement of a lawsuit claiming that a boy's use of its antipsychotic drug Risperdal caused abnormal breast growth.
The settlement—whose terms were confidential—averted a civil trial scheduled to begin Monday in which plaintiffs' lawyers intended to summon J&J Chief Executive Alex Gorsky as a witness. Mr. Gorsky previously held leadership roles at the J&J division responsible for marketing Risperdal during the period when the boy's alleged injury occurred.
Robert C. Hilliard, an attorney for the plaintiff, told a judge in the Philadelphia Court of Common Pleas Monday "this case has reached a final resolution." He said the settlement amount was confidential.
